Literature DB >> 24828660

Prospective CT screening for lung cancer in a high-risk population: HIV-positive smokers.

Alicia Hulbert1, Craig M Hooker, Jeanne C Keruly, Travis Brown, Karen Horton, Eliott Fishman, Kristen Rodgers, Beverly Lee, Celis Sam, Salina Tsai, Elizabeth Weihe, Genevieve Pridham, Brad Drummond, Christian Merlo, Maria Geronimo, Michelle Porter, Solange Cox, Dan Li, Marian Harline, Mario Teran, John Wrangle, Beatrice Mudge, Gregory Taylor, Gregory D Kirk, James G Herman, Richard D Moore, Robert H Brown, Malcolm V Brock.   

Abstract

BACKGROUND: Epidemiological evidence suggests that HIV-infected individuals are at increased risk of lung cancer, but no data exist because large computed tomography (CT) screening trials routinely exclude HIV-infected participants.
METHODS: From 2006 to 2013, we conducted the world's first lung cancer screening trial of 224 HIV-infected current/former smokers to assess the CT detection rates of lung cancer. We also used 130 HIV-infected patients with known lung cancer to determine radiographic markers of lung cancer risk using multivariate analysis.
RESULTS: Median age was 48 years with 34 pack-years smoked. During 678 person-years, one lung cancer was found on incident screening. Besides this lung cancer case, 18 deaths (8%) occurred, but none were cancer related. There were no interim diagnoses of lung or extrapulmonary cancers. None of the pulmonary nodules detected in 48 participants at baseline were diagnosed as cancer by study end. The heterogeneity of emphysema across the entire lung as measured by CT densitometry was significantly higher in HIV-infected subjects with lung cancer compared with the heterogeneity of emphysema in those without HIV (p ≤ 0.01). On multivariate regression analysis, increased age, higher smoking pack-years, low CD4 nadir, and increased heterogeneity of emphysema on quantitative CT imaging were all significantly associated with lung cancer.
CONCLUSIONS: Despite a high rate of active smoking among HIV-infected participants, only one lung cancer was detected in 678 patient-years. This was probably because of the young age of participants suggesting that CT screening of high-risk populations should strongly consider advanced age as a critical inclusion criterion. Future screening trials in urban American must also incorporate robust measures to ensure HIV patient compliance, adherence, and smoking cessation.

Entities:  

Mesh:

Year:  2014        PMID: 24828660      PMCID: PMC4023914          DOI: 10.1097/JTO.0000000000000161

Source DB:  PubMed          Journal:  J Thorac Oncol        ISSN: 1556-0864            Impact factor:   15.609


  50 in total

1.  Association of cancer with AIDS-related immunosuppression in adults.

Authors:  M Frisch; R J Biggar; E A Engels; J J Goedert
Journal:  JAMA       Date:  2001-04-04       Impact factor: 56.272

2.  Lung cancer in persons with AIDS in Italy, 1985-1998.

Authors:  Luigino Dal Maso; Jerry Polesel; Diego Serraino; Silvia Franceschi
Journal:  AIDS       Date:  2003-09-26       Impact factor: 4.177

3.  Screening for lung cancer with low-dose helical computed tomography: anti-lung cancer association project.

Authors:  Tomotaka Sobue; Noriyuki Moriyama; Masahiro Kaneko; Masahiko Kusumoto; Toshiaki Kobayashi; Ryosuke Tsuchiya; Ryutaro Kakinuma; Hironobu Ohmatsu; Kanji Nagai; Hiroyuki Nishiyama; Eisuke Matsui; Kenji Eguchi
Journal:  J Clin Oncol       Date:  2002-02-15       Impact factor: 44.544

4.  Factors associated with the failure of HIV-positive persons to return for scheduled medical visits.

Authors:  Claudio Arici; Diego Ripamonti; Franco Maggiolo; Marco Rizzi; Maria Grazia Finazzi; Patrizio Pezzotti; Fredy Suter
Journal:  HIV Clin Trials       Date:  2002 Jan-Feb

5.  Early Lung Cancer Action Project: overall design and findings from baseline screening.

Authors:  C I Henschke; D I McCauley; D F Yankelevitz; D P Naidich; G McGuinness; O S Miettinen; D M Libby; M W Pasmantier; J Koizumi; N K Altorki; J P Smith
Journal:  Lancet       Date:  1999-07-10       Impact factor: 79.321

6.  Computed tomographic diagnosis of bronchogenic carcinoma in HIV-infected patients.

Authors:  M Bazot; J Cadranel; A Khalil; S Benayoun; B Milleron; J M Bigot; M F Carette
Journal:  Lung Cancer       Date:  2000-06       Impact factor: 5.705

7.  Screening for lung cancer with low-dose spiral computed tomography.

Authors:  Stephen J Swensen; James R Jett; Jeff A Sloan; David E Midthun; Thomas E Hartman; Anne-Marie Sykes; Gregory L Aughenbaugh; Frank E Zink; Shauna L Hillman; Gayle R Noetzel; Randolph S Marks; Amy C Clayton; Peter C Pairolero
Journal:  Am J Respir Crit Care Med       Date:  2002-02-15       Impact factor: 21.405

8.  Overdiagnosis in low-dose computed tomography screening for lung cancer.

Authors:  Edward F Patz; Paul Pinsky; Constantine Gatsonis; Jorean D Sicks; Barnett S Kramer; Martin C Tammemägi; Caroline Chiles; William C Black; Denise R Aberle
Journal:  JAMA Intern Med       Date:  2014-02-01       Impact factor: 21.873

9.  Incidence of non-AIDS-defining cancers before and during the highly active antiretroviral therapy era in a cohort of human immunodeficiency virus-infected patients.

Authors:  Magid Herida; Murielle Mary-Krause; Régis Kaphan; Jacques Cadranel; Isabelle Poizot-Martin; Christian Rabaud; Nathalie Plaisance; Hervé Tissot-Dupont; François Boue; Jean-Marie Lang; Dominique Costagliola
Journal:  J Clin Oncol       Date:  2003-09-15       Impact factor: 44.544

10.  Results of three-year mass screening programme for lung cancer using mobile low-dose spiral computed tomography scanner.

Authors:  S Sone; F Li; Z G Yang; T Honda; Y Maruyama; S Takashima; M Hasegawa; S Kawakami; K Kubo; M Haniuda; T Yamanda
Journal:  Br J Cancer       Date:  2001-01-05       Impact factor: 7.640

View more
  17 in total

Review 1.  Lung cancer in HIV-infected patients in the combination antiretroviral treatment era.

Authors:  José Moltó; Teresa Moran; Guillem Sirera; Bonaventura Clotet
Journal:  Transl Lung Cancer Res       Date:  2015-12

2.  Short-term outcomes for lung cancer resection surgery in HIV infection.

Authors:  Keith M Sigel; Kimberly Stone; Juan P Wisnivesky; Lesley S Park; Chung Yin Kong; Michael J Silverberg; Sheldon Brown; Matthew Goetz; Maria C Rodriguez-Barradas; Cynthia Gibert; Fatma Shebl; Roger Bedimo; Roxanne Wadia; Joseph King; Kristina Crothers
Journal:  AIDS       Date:  2019-07-01       Impact factor: 4.177

Review 3.  Lung cancer in persons with HIV.

Authors:  Keith Sigel; Alain Makinson; Jonathan Thaler
Journal:  Curr Opin HIV AIDS       Date:  2017-01       Impact factor: 4.283

Review 4.  HIV-Associated Cancers and Related Diseases.

Authors:  Robert Yarchoan; Thomas S Uldrick
Journal:  N Engl J Med       Date:  2018-03-15       Impact factor: 91.245

Review 5.  Disparities in Lung Cancer Screening: A Review.

Authors:  Diane N Haddad; Kim L Sandler; Louise M Henderson; M Patricia Rivera; Melinda C Aldrich
Journal:  Ann Am Thorac Soc       Date:  2020-04

Review 6.  Lung Malignancies in HIV Infection.

Authors:  Keith Sigel; Robert Pitts; Kristina Crothers
Journal:  Semin Respir Crit Care Med       Date:  2016-03-14       Impact factor: 3.119

Review 7.  Cancer prevention in HIV-infected populations.

Authors:  Priscila H Goncalves; Jairo M Montezuma-Rusca; Robert Yarchoan; Thomas S Uldrick
Journal:  Semin Oncol       Date:  2015-09-08       Impact factor: 4.929

Review 8.  Non-infectious Pulmonary Diseases and HIV.

Authors:  M Triplette; K Crothers; E F Attia
Journal:  Curr HIV/AIDS Rep       Date:  2016-06       Impact factor: 5.071

9.  Ventilation Heterogeneity and Its Association with Nodule Formation Among Participants in the National Lung Screening Trial-A Preliminary Investigation.

Authors:  David A Kaminsky; Nirav Daphtary; Raul S J Estepar; Taka Ashikaga; Lukas Mikulic; Jeffrey Klein; C Matthew Kinsey
Journal:  Acad Radiol       Date:  2019-08-27       Impact factor: 5.482

Review 10.  Maintaining lung health with longstanding HIV.

Authors:  Paul Collini; Alison Morris
Journal:  Curr Opin Infect Dis       Date:  2016-02       Impact factor: 4.915

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.